Drug Trial Radar · NCT03987763
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Oct 22, 2019
Primary completion
Nov 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
IDP-122 LotionDrug
Topical
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics: Maximum Observed Drug (Halobetasol Propionate) Concentration in Plasma (Cmax) of IDP-122 Lotion AnalytesTime frame: 0 (predose), 1, 2, 4, 8, 12, and 24 hours postdose
Locations
9 sites in 3 countries. Site status is shown where the registry gives one.
Bausch Site 11
Fountain Valley, California
Bausch Site 2
Thousand Oaks, California
Bausch Site 07
Doral, Florida
Bausch Site 3
Miami, Florida
Bausch Site 06
Miami, Florida
Bausch Site 05
Spartanburg, South Carolina
Bausch Site 1
Spokane, Washington
Bausch Site 12
Santo Domingo, Dominican Republic
Bausch Site 4
Panama City, Panama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.